Oncolytic Viruses Driven by Tumor-Specific Promoters
Jayson Hardcastle, Kazuhiko Kurozumi, E. Antonio Chiocca and Balveen Kaur
Pages 181-189 (9)
Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumorspecific transcriptional events.
Oncolytic viruses, adenovirus, HSV-1, cancer, transcriptional regulation, promoter
Dardinger Laboratory for Neuro-Oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University, 410 West 12th Avenue, Columbus, Ohio 43210, USA.